文献库搜索 | GeneLibs

Horvat(NK),Saint-Cloud(M),Bint Abdullah Mu... Cancer Immunol Res 2026-06-02

...Kras/p53-driven lung cancer models that demonstrate acquired or intrinsic resistance to ICIs, we performed single-cell R...

Dumbrava(EE),Shapiro(GI),Parikh(AR),Johnso... N Engl J Med 2026-02-26

...KRAS wild-type tumor and received a dose of at least 1150 mg once daily. Confirmed responses were seen across multiple t...

Yadav(B),Kollur(SP),Ali(A),Arora(P),Gupta(... Discov Oncol 2026-05-18

...KRAS, TP53, CDKN2A, and SMAD4 mutations that fuel Pancreatic cancer progression and stromal desmoplasia. Diverse peptide...

Rodon(J),O'Neil(B),Lim(C),Ammakkanavar(NR)... Invest New Drugs 2026-08-00

KRAS-mutant NSCLC resistance to MEK inhibitors (MEKi) is related to compensatory upregulation of fibroblast growth facto...

Ji(C),Wu(X),Zhao(L),Zhang(S),Zhang(H) J Vis Exp 2026-04-28

...KRAS)-mutant and wild-type tumors demonstrated the opposite pattern. Higher programmed death-ligand 1 (PD-L1) expression...

Seika(P),Puttapaka(S),Hong(SM),Scott(A),Sl... bioRxiv 2026-05-06

...KRAS gene expression. A subset of adult murine colonic myenteric neurons expressed PCSK1 and M-ENK. M-ENK dose-dependent...

Kim(MC),Jung(HJ),Kang(MC),Kim(HY),Jang(SS)... Comput Struct Biotechnol J None

...KRAS-mutation-associated probe screening. Operationally, ISSM supports rapid post-sequencing triage, prioritization of c...

ALTamimi(AO),Elemam(NM),Hafezi(S),Saber-Ay... Front Pharmacol None

...KRAS, BRAF, PIK3CA, and TP53, on tumor progression and highlight their dynamic interactions with the TME, which can modu...

Hauptschein(D),Uson Junior(PLS),Borad(MJ) Chin Clin Oncol 2026-04-00

...KRAS, TP53, SMAD4, and cfDNA methylation panels, and for CCA with FGFR2, IDH1/2, and BAP1 mutations detected in bile-der...

Tooming(M),Rekker(K),Toome(K),Roht(L),Laid... Acta Oncol 2026-05-18

...KRAS, and BRAF. Additional therapeutic targets were identified across diverse biomarkers. HRD was present in 53.2% of te...